Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)

Next Previous
Trial Profile

Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Cushing syndrome
  • Focus Therapeutic Use
  • Acronyms CATALYST
  • Sponsors Corcept Therapeutics

Most Recent Events

  • 21 Apr 2025 Primary endpoint (Part 2 Treatment Phase: Effect of Treatment on Hypercortisolism without Abnormal Adrenal CT Scan) has been met, according to a Corcept Therapeutics Media Release.
  • 21 Apr 2025 According to a Corcept Therapeutics Media Release, complete results will be presented at the American Diabetes Association's 85th Scientific Sessions on June 23, 2025, at a symposium titled: "Treatment of Hypercortisolism in People with Difficult-to-Control Type 2 Diabetes - Final Results of the CATALYST Trial.
  • 21 Apr 2025 According to a Corcept Therapeutics Media Release, data from this study were published in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top